We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
+9.03%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$5.72B
AUM Growth
+$377M
Cap. Flow
-$47.5M
Cap. Flow %
-0.83%
Top 10 Hldgs %
18.31%
Holding
1,615
New
130
Increased
604
Reduced
665
Closed
130

Sector Composition

Rank Sector Weight
1 Technology 19.17%
2 Financials 10.88%
3 Healthcare 10.31%
4 Consumer Discretionary 9.37%
5 Industrials 8.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WLY icon
1176
John Wiley & Sons Class A
WLY
$2.63B
$339K 0.01%
5,920
-2,575
-30% -$139K
BST icon
1177
BlackRock Science and Technology Trust
BST
$1.6B
$337K 0.01%
6,753
ELS icon
1178
Equity Lifestyle Properties
ELS
$12.7B
$337K 0.01%
3,847
-1,054
-22% -$88.7K
METV icon
1179
Roundhill Ball Metaverse ETF
METV
$207M
$337K 0.01%
+22,200
New +$342K
RIVN icon
1180
Rivian
RIVN
$22.9B
$336K 0.01%
+3,242
New +$374K
SONO icon
1181
Sonos
SONO
$1.72B
$336K 0.01%
11,260
-275
-2% -$8.75K
VOOG icon
1182
Vanguard S&P 500 Growth ETF
VOOG
$25.5B
$336K 0.01%
6,690
+1,362
+26% +$66K
LSXMA
1183
DELISTED
Liberty Media Corporation Series A Liberty SiriusXM Common Stock
LSXMA
$336K 0.01%
8,999
-167
-2% -$6.16K
TAP icon
1184
Molson Coors Class B
TAP
$7.76B
$334K 0.01%
7,194
-483
-6% -$22.2K
CLR
1185
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$334K 0.01%
7,467
+400
+6% +$19K
GBT
1186
DELISTED
Global Blood Therapeutics, Inc.
GBT
$332K 0.01%
+11,327
New +$351K
MIN
1187
Aberdeen Intermediate Income Fund
MIN
$274M
$331K 0.01%
92,259
+550
+0.6% +$1.98K
SDGR icon
1188
Schrodinger
SDGR
$1.13B
$331K 0.01%
9,491
-1,816
-16% -$82.9K
FTF
1189
Franklin Limited Duration Income Trust
FTF
$232M
$328K 0.01%
36,126
+143
+0.4% +$1.29K
AMN icon
1190
AMN Healthcare
AMN
$1.31B
$327K 0.01%
2,675
+334
+14% +$37.1K
IWV icon
1191
iShares Russell 3000 ETF
IWV
$19.4B
$327K 0.01%
1,180
+3
+0.3% +$813
ARKQ icon
1192
ARK Autonomous Technology & Robotics ETF
ARKQ
$1.87B
$326K 0.01%
4,234
-186
-4% -$15.2K
YORW icon
1193
York Water
YORW
$501M
$326K 0.01%
6,542
FTHY
1194
First Trust High Yield Opportunities 2027 Term Fund
FTHY
$501M
$324K 0.01%
16,004
+5,805
+57% +$119K
QQQH
1195
NEOS Nasdaq-100 Hedged Equity Income ETF
QQQH
$372M
$324K 0.01%
5,800
REM icon
1196
iShares Mortgage Real Estate ETF
REM
$536M
$323K 0.01%
9,359
-100
-1% -$3.65K
SRC
1197
DELISTED
SPIRIT REALTY CAPITAL, INC.
SRC
$323K 0.01%
6,705
+40
+0.6% +$1.9K
NRK icon
1198
Nuveen New York AMT-Free Quality Municipal Income Fund
NRK
$898M
$321K 0.01%
23,294
-1,430
-6% -$19.7K
CET
1199
Central Securities Corp
CET
$1.57B
$320K 0.01%
7,174
+584
+9% +$24.9K
FUBO icon
1200
FuboTV Inc
FUBO
$248M
$320K 0.01%
1,720
-197
-10% -$55.4K

Similar funds

Oppenheimer & Co's Q4 2021 Portfolio in Review

As of Q4 2021, Oppenheimer & Co held 1,615 positions worth $5.72B, up 7.1% from $5.34B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Oppenheimer & Co's Q4 2021 filing shows 130 new, 604 increased, 665 reduced and 130 closed positions. Its largest new stake was Invesco Total Return Bond ETF: 132,838 shares worth $7.49M. The largest sale was Global X S&P 500 Covered Call ETF, an estimated $49.9M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.

  • Oppenheimer & Co's largest Q4 2021 buy was Invesco Total Return Bond ETF: 132,838 shares worth $7.49M.
  • Oppenheimer & Co added most to Canadian Pacific Kansas City in Q4 2021, an estimated $7.48M increase.
  • Oppenheimer & Co's biggest Q4 2021 reduction was Global X S&P 500 Covered Call ETF, cutting an estimated $49.9M.
  • Oppenheimer & Co fully exited Kansas City Southern in Q4 2021, selling an estimated $6.61M.
  • Oppenheimer & Co's ten largest holdings make up 18% of its $5.72B portfolio in Q4 2021.
  • Oppenheimer & Co opened 130 new positions and closed 130 in Q4 2021.
  • Oppenheimer & Co's portfolio value rose 7.1% quarter-over-quarter to $5.72B.

Based on Oppenheimer & Co's 13F filing for Q4 2021, filed 2 Feb 2022.